The Op-104 Anchor Study: A Phase 1/2 Study Of Safety And Efficacy Of Melflufen And Dexamethasone In Combination With Either Bortezomib Or Daratumumab In Patients With Rrmm; First Report On Phase 1 Data

Ludek Pour,Miquel Granell,Roman Hajek,Albert Oriol,Yvonne Efebera,Jacques Delaunay,Katell Le Du,Jean-Richard Eveillard,Lionel Karlin,Vladimir Maisnar, Joaquin Martinez Lopez,Maria-Victoria Mateos,Jan Moreb,Vincent Ribrag,Paul Richardson,Jan Straub,Catriona Byrne,Christian Jacques,Hanan Zubair,Enrique Ocio

BLOOD（2018）

引用 3|浏览3

暂无评分

摘要

Background:Recent improvements in the treatment of relapsed-refractory multiple myeloma (RRMM) have significantly increased the survival of patients. Despite the availability of new therapies, only 20-30% of the RRMM patients respond to any particular treatment and new approaches are clearly needed.

查看译文

关键词

daratumumab,rrmm,,melflufen,dexamethasone,efficacy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要